Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
This study tests whether having a patient navigator help guide prostate cancer patients through the clinical trial process increases enrollment in cancer research studies. Researchers will compare two approaches: one with intensive support from a navigator versus one with minimal support, both at academic hospitals and community cancer centers.
Key Objective:The trial aims to identify whether patient navigation services can effectively help more cancer patients enroll in and access clinical trials.
Who to Consider:Prostate cancer patients at participating academic or community cancer centers who are interested in learning about available clinical trials and potentially enrolling in cancer research should consider participating.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in academic and community cancer centers. Patient navigation is a strategy for increasing patients access to cancer care by helping the participant overcome barriers in the participants communities and within the health care system by providing a bridge between the patient and the health care system. The primary objective of this study is to determine if a high intensity patient navigation program will improve patients enrollment on clinical trial in comparison to a low intensity patient navigation. Participants who agree to participate and are eligible will be randomly assigned to either the high intensity or low intensity approach.
Eligibility Criteria
1. Age ≥ 18 years 2. Patient with a current diagnosis of a primary solid tumor including: prostate cancer and kidney cancer 3. Being seen at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins University (JHU) or Wellspan Health Center 4. Available therapeutic trial for the patient as determined through pre-screening/medical record review